Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, March 15, 2013 - BAT


Submission Type: BLA    Submission ID: 125462/0    Office: OBRR Product:
Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)
Cangene Corporation
Telecon Date/Time: 15-MAR-2013 01:30 PM        Initiated by FDA? Yes
Telephone Number: (204) 275-4208
Communication Categorie(s):
1. Information Request
Author: ROBERT FISHER Telecon Summary:
BAT product stability and dating period discussion FDA Participants: Robert W. Fisher, Dorothy Scott Non-FDA Participants: Terry Kraynyk
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:
FDA initiated call to Cangene to request stability testing details for lots of BAT in the SNS. FDA is trying to determine what dating period would be supported by the BAT potency data since serotype A potency appears to be the limiting factor.
FDA requested that Cangene provide:
• A list of BAT lots that would be greater than 48 months at the time of product licensure including the stability testing schedule and next time point of testing.
• The addition of Serotype A potency testing to all lots according to the time points of the regular stability program. FDA indicated that depending on the stability (potency) profile the expanded testing might be revisited in the future
Provide PMC wording to the agency to capture the addition of the Serotype A potency testing for all lots according to the time points of the regular stability program.

Page Last Updated: 06/24/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English